October 27, 2022 by Chain Drug Review
NACDS
Leading Headlines, Pharmacy
ARLINGTON, Va. — In reaction to President Biden’s press conference this week where he called on pharmacies to administer more boosters, NACDS has responded to the White House by issuing a letter laying out how the Administration must act now to ensure patient access to critical vaccines. “We are writing to support recent efforts to
October 26, 2022 by Chain Drug Review
Dr. Lauren Lyles-Stolz, NACDS
Leading Headlines, Pharmacy
ARLINGTON, Va. – Dr. Lauren Lyles-Stolz, PharmD, has joined the staff team of the National Association of Chain Drug Stores (NACDS). She fills the new role of senior director of reimbursement, innovation and advocacy. Most recently, she served as health legislative assistant for U.S. Rep. Bradley S. Schneider (D-Ill.). At NACDS, she will serve as
October 20, 2022 by Chain Drug Review
NACDS
Leading Headlines, Retail News
ARLINGTON, Va. – As of October 17, for the first time, American adults with mild-to-moderate hearing loss have the ability to buy hearing aids on an over-the-counter (OTC) basis at retailers across the country. The National Association of Chain Drug Stores (NACDS)-backed move — which will greatly enhance patients’ access to hearing aids — comes out
October 4, 2022 by Chain Drug Review
NACDS
Leading Headlines, Pharmacy
BOSTON – Exhibitors at the National Association of Chain Drug Stores (NACDS) Total Store Expo, held August 27-29 at the Boston Convention & Exhibition Center (BCEC), donated thousands of consumer goods to be dispersed to local non-profit organizations. The NACDS Total Store Expo is the largest gathering of retailers and suppliers in the health and
September 28, 2022 by Chain Drug Review
NACDS, Nutrition and Health, White House Conference on Hunger
Leading Headlines, Pharmacy
WASHINGTON – NACDS members have served with “lights on, doors open” in the nation’s COVID-19 response. At today’s White House Conference on Hunger, Nutrition and Health, the Association is reminding policymakers and collaborators that broader health and wellness solutions also can be found as close as the nearest pharmacy. NACDS president & CEO Steven C.
September 26, 2022 by Chain Drug Review
Biden, NACDS, Steve Anderson
Leading Headlines, Pharmacy
ARLINGTON, Va. – On September 22, 2022, NACDS issued the following open letter: Dear President Biden and the White House COVID-19 Task Force: Thank you for your engagement and leadership throughout the COVID-19 pandemic. The National Association of Chain Drug Stores (NACDS) represents regional and national drug stores, supermarkets, and mass merchants with pharmacies. The
August 25, 2022 by Chain Drug Review
NACDS, Steven Anderson
Leading Headlines, Pharmacy, Retail News
ARLINGTON, Va. — With the 2022 NACDS Total Store Expo set to launch, the Boston Business Journal this morning published an op-ed authored by NACDS President & CEO Steven Anderson. The opinion piece centers on the pharmacy industry’s mighty and ongoing role in the COVID-19 response; legislative action that must be taken to help sustain Americans’ access
August 22, 2022 by Chain Drug Review
2022 Total Store Expo, NACDS
Leading Headlines, Pharmacy, Retail News
BOSTON — The 2022 National Association of Chain Drug Stores (NACDS) Total Store Expo kicks off August 27-29. The highly anticipated event — returning in-person for the first time since 2019 — will bring together NACDS-member retailers and suppliers nationwide to Boston, Mass., for vibrant discussion and collaboration. Check out the NACDS Total Store Expo “Know
August 1, 2022 by Chain Drug Review
Kate Ilahi and Whitney Jones, NACDS
Leading Headlines, Pharmacy
ARLINGTON, Va. – The National Association of Chain Drug Stores (NACDS) announced on Monday the appointment of and Whitney Jones, each in the role of director of Congressional relations. Ilahi has served as director of government relations for 340B Health since January 2020. Jones has served as health policy analyst for the U.S. Senate Republican
July 20, 2022 by NACDS staff
NACDS
Leading Headlines, Pharmacy
ARLINGTON, Va. — The National Association of Chain Drug Stores is engaging in the drive for PBM reform on three fronts, the trade association said Wednesday, pointing to recent efforts in the media and in the state and federal government arenas. 1. NACDS Takes on “Defense of PBM” Op-ed in The Wall Street Journal Last
July 19, 2022 by Chain Drug Review
and Health, NACDS, Nutrition, White House Conference on Hunger
Leading Headlines, Pharmacy
WASHINGTON — As part of the bold “NACDS 2023” initiative, NACDS has issued recommendations for the upcoming White House Conference on Hunger, Nutrition, and Health and for the Biden Administration’s policy agenda on these issues. Described by the NACDS leadership during the 2022 NACDS Annual Meeting, “NACDS 2023” is a strategic approach that reflects NACDS chain and
July 18, 2022 by David Pinto
CVS Health, NACDS, Revlon
July 18, 2022, Opinion
Two stunning news stories, breaking simultaneously, woke up the sometimes comatose world of mass retailing as spring 2022 slipped, almost without notice, into summer. First of the two was the once unthinkable: Revlon, once the doyenne of the mass market cosmetics business, filed for Chapter 11 bankruptcy protection. To those in the know, both inside
July 15, 2022 by Chain Drug Review
NACDS
Leading Headlines, Pharmacy
ARLINGTON, Va. — NACDS submitted on Tuesday recommendations to the Biden Administration that would help operationalize improved access to Paxlovid (nirmatrelvir and ritonavir) and maximize public benefit of this treatment, particularly among individuals at high-risk of progression to severe COVID-19. READ LETTER NACDS’ recommendations follow the July 6 announcement by the U.S. Food and Drug
July 6, 2022 by Chain Drug Review
NACDS, National Community Pharmacists Association
Leading Headlines, Pharmacy
WASHINGTON – Pharmacy groups praised the U.S. Food and Drug Administration on the revised Emergency Use Authorization (EUA) for Paxlovid (nirmatrelvir and ritonavir), to authorize state-licensed pharmacists to prescribe Paxlovid to eligible patients, with certain limitations to ensure appropriate patient assessment and prescribing of Paxlovid. “The FDA’s action is an extremely important revision for patient access